# Norton-Simon hypothesis and dose-dense chemotherapy

Source: https://onco.cc/technologies/norton-simon-hypothesis/  
OnCo record `norton-simon-hypothesis` (Technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Because tumours regrow fastest when small, the best way to finish them is to give the same chemotherapy doses closer together. The idea, from Larry Norton and Richard Simon, was proved in breast cancer by the CALGB 9741 trial and made two-weekly chemotherapy a standard.

## Summary

Norton and Simon argued in 1977 that chemotherapy kills tumour cells in proportion to the tumour's growth rate at that moment, and, since Gompertzian growth is fastest in small tumours, the residual disease after each cycle regrows quickly between cycles. Shortening the interval rather than raising the dose should therefore improve cure rates. CALGB 9741 (2003) tested two-weekly against three-weekly adjuvant chemotherapy with growth factor support in node-positive breast cancer and found better disease-free and overall survival, establishing dose-dense scheduling; the Early Breast Cancer Trialists' meta-analysis later confirmed a survival gain across trials.

## Fields

- Kind: Technology
- Status: established
- Last checked: 2026-09-17
- Tags: mathematical-model
- Principle: Kill rate is proportional to the Gompertzian growth rate of the tumour, so regrowth between cycles is the enemy and shorter intervals matter more than higher doses.
- Since: 1977
- Strengths: Confirmed in randomised trials and meta-analysis; Uses existing drugs; Explains failure of dose escalation in some settings
- Limitations: Needs growth factor support; Benefit varies by cancer; Assumes Gompertzian kinetics

## Sources

- CALGB 9741, Citron 2003: https://doi.org/10.1200/JCO.2003.09.081
- EBCTCG 2019 meta-analysis: https://doi.org/10.1016/S0140-6736(18)33137-4

## Connected records

- cancers: [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/), [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- fronts: [AI & Computation](https://onco.cc/fronts/ai-computation/), [Drug Discovery Platforms](https://onco.cc/fronts/drug-discovery/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Gompertzian tumour growth](https://onco.cc/technologies/gompertzian-growth-model/), [Growth factors: G-CSF and febrile neutropenia prevention](https://onco.cc/technologies/g-csf-growth-factors/)

---
JSON: https://onco.cc/api/v1/entities/norton-simon-hypothesis.json